Table 2.

Expression of CLDN15 and other markers for MPM in three types of MPMs and lung adenocarcinoma tissues.

	CLDN15	Calretinin	WT-1	D2-40	Total
Epithelioid-type MPM	26 (93%)**	26 (93%)**	14 (50%)	24 (86%)*	28
Biphasic-type MPM	6 (75%)	6 (75%)	5 (63%)	6 (75%)	8
Sarcomatoid-type MPM	3 (50%)	2 (33%)	2 (33%)	4 (67%)	6
Total MPM	35 (83%)*	34 (81%)*	21 (50%)	34 (81%)*	42
Lung adenocarcinoma	4/50	4/40	1/40	0/40
Specificity	92%	90%	98%	100%

	CL15 or Cal	CL15 or WT1	CL15 or D2-40	Cal or WT1	Cal or D2-40	WT1 or D2-40
Epithelioid-type MPM	28 (100%)	27 (96%)	28 (100%)	27 (96%)	27 (96%)	26 (93%)
Biphasic-type MPM	7 (88%)	7 (88%)	7 (88%)	7 (88%)	8 (100%)	8 (100%)
Sarcomatoid-type MPM	4 (67%)	4 (67%)	5 (83%)	3 (50%)	5 (83%)	5 (83%)
Total MPM	39 (93%)	38 (90%)	40 (95%)	37 (88%)	40 (95%)	39 (93%)
Lung adenocarcinoma	7/40	5/40	4/40	5/40	4/40	1/40
Specificity	83%	88%	90%	88%	90%	98%

	CL15 & Cal	CL15 & WT1	CL15 & D2-40	Cal & WT1	Cal & D2-40	WT1 & D2-40
Epithelioid-type MPM	24 (71%)	13 (46%)†	22 (79%)	13 (46%)†	23 (82%)‡	12 (43%)†
Biphasic-type MPM	5 (63%)	4 (50%)	5 (63%)	4 (50%)	4 (50%)	3 (38%)
Sarcomatoid-type MPM	1 (17%)	1 (17%)	2 (33%)	1 (17%)	1 (17%)	1 (17%)
Total MPM	30 (71%)	18 (43%)	29 (69%)‡	18 (43%)	28 (67%)	16 (38%)†
Lung adenocarcinoma	1/40	0/40	0/40	0/40	0/40	0/40
Specificity	98%	100%	100%	100%	100%	100%

*p < 0.05; **p < 0.005 higher than the sensitivity of WT-1; ^†p < 0.05 lower than CL15&Cal; ^‡p < 0.05 higher than WT1&D2-40. Other pairs were not significantly different.